On 14 September 2026, Guangdong Tianyu Semiconductor Co., Ltd. (02658.HK) announced that its Board approved an H share repurchase plan under the general mandate granted by shareholders on 19 May 2026, covering up to 5,899,042 H shares, or 10% of the issued H shares as at the date the mandate was granted, with the repurchase price not exceeding the average closing price over the preceding five trading days by 5% or more.
On 14 September 2026, OneRobotics (Shenzhen) Co., Ltd. (06600.HK) announced that the trustee of its 2026 H Share Incentive Scheme purchased a further 101,200 H shares on the market between 28 August and 14 September 2026 at approximately HKD 39.48 to approximately HKD 53.00 per share, for a total consideration of approximately HKD 5.0 million; following the purchase, the trustee holds 653,200 H shares, representing approximately 0.290% of the total issued H shares.
On 14 September 2026, BOAN BIOTECH (06955.HK) announced that the investigational new drug application for its PD-1/IL-2 antibody-cytokine prodrug BA1203 has been approved by the Centre for Drug Evaluation of the National Medical Products Administration of the PRC, with the drug intended for the treatment of multiple solid tumours.
On 14 September 2026, WEIHAI BANK (09677.HK) announced that the Bank has successfully issued its 2026 green financial bonds (first tranche) in the national interbank bond market, with an issue size of RMB 500 million, a coupon rate of 1.65% and a term of three years.
On 14 September 2026, HENGRUI PHARMA (01276.HK) announced that its subsidiary Beijing Shengdi Pharmaceutical Co., Ltd. received a Notice of Acceptance from the National Medical Products Administration, with the marketing application for SHR-2004 injection, a Class 1 innovative drug and coagulation factor XI monoclonal antibody, accepted for the proposed indication of preventing venous thromboembolism in adult patients undergoing elective knee replacement surgery, under acceptance number CXSS2600151.
On 14 September 2026, YIDU TECH (02158.HK) announced that Yidu Cloud (Beijing) Technology Co., Ltd., an affiliate of the Company, received a notice of award and won the bid for the ageing and health innovation translation construction project of the National Clinical Medical Research Centre for Geriatric Diseases of Xiangya Hospital of Central South University, with a total project amount of approximately RMB 3,565,000.
On 14 September 2026, HX COLDCHAIN (01641.HK) announced that it subscribed, using idle funds, for a wealth management product in the amount of RMB 20 million with Bank of Communications Co., Ltd. Hunan Provincial Branch, namely the "Yuntong Wealth" 35-day fixed-term structured deposit with an expected annualised return of 0.65% to 1.58%, constituting a discloseable transaction under the Listing Rules.
On 14 September 2026, CMS (00867.HK) announced that CMS-D001 tablets, an innovative drug, obtained a drug clinical trial approval notice issued by the National Medical Products Administration on 11 September 2026 and received by the Company on 14 September, with the NMPA agreeing to clinical trials evaluating the efficacy and safety of the drug in treating the systemic lupus erythematosus indication.
On 14 September 2026, CSPC PHARMA (01093.HK) announced that it presented, as an oral presentation at the 2026 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, the Phase I/II clinical study data of SYS6010 combined with Enlangsuba monoclonal antibody for the treatment of previously untreated driver-gene-negative advanced NSCLC, with confirmed objective response rates of 58.9% and 49.2% in the overall population under the two regimens.
On September 14, 2026, the three major Hong Kong stock indices moved mixed, with the Hang Seng Index up 0.45%, the Hang Seng TECH Index down slightly by 0.06%, and the Hang Seng China Enterprises Index up 0.46%. The full-day market turnover was 192.6 billion HKD. On the board, among Stock Connect constituent stocks, HQVT surged 29.69% as the company presented multispectral AI products and solutions at the 2026 China Emergency Exhibition. Southbound capital recorded net buying of HK$4.471 billion on the day. Of this, Stock Connect (Shanghai) recorded net buying of HK$1.671 billion, and Stock Connect (Shenzhen) recorded net buying of HK$2.8 billion.
On September 14, 2026, the three major Hong Kong stock indices moved mixed, with the Hang Seng Index up 0.45%, the Hang Seng TECH Index down slightly by 0.06%, and the Hang Seng China Enterprises Index up 0.46%. AI concept stocks came under broad pressure on the day, with the LLM sector under broad pressure, AI Chips mixed, and the Autonomous Driving sector mostly declining.
On 14 September 2026, LEADS BIOLABS-B (09887.HK) announced that the Company presented updated Phase II clinical study data for Vilxin® (Opatilimab, PD-L1/4-1BB bispecific antibody) in combination with chemotherapy as first-line treatment for NSCLC in an oral presentation at WCLC 2026; as at 1 July 2026, among 62 efficacy-evaluable patients, the ORR in the overall patient population reached 71.0%, the DCR reached 95.2% and the 6-month PFS rate reached 70.6%.
on September 14, 2026, the three major Hong Kong indices moved mixed, with the Hang Seng Index up 0.45%, the Hang Seng TECH Index down slightly by 0.06%, and the Hang Seng China Enterprises Index up 0.46%. The full-day market turnover was 192.6 billion HKD, Southbound funds saw a net inflow of 4.471 billion HKD.
On 14 September 2026, CR HOLDINGS (01911.HK) announced that China Renaissance Pan Asia Investment Advisory (Beijing) Co., Ltd., an indirect wholly-owned subsidiary of the Company, acted as sole financial adviser to the latest Series B financing of AlphaPai, an artificial intelligence application focused on financial scenarios.
On September 14, 2026, the main theme of the HK shares ETFs market switched to biotech. ChinaAMC Hang Seng Hong Kong Biotech Index ETF rose 4.07% to lead, followed by CSOP Hang Seng Biotech ETF and Global X China Biotech ETF, with biotech ETFs sweeping the top three gainers; dividend, EV and new-economy themes posted modest gains. On the downside, Phillip HK Newly Listed Equities Index ETF plunged 6.87% to top the losers, while Korea and semiconductor themes fell sharply, with Xtrackers MSCI Korea UCITS ETF, CSOP KOSPI 200 ETF and E Fund (HK) Solactive Asia Semiconductor Select Index ETF all dropping more than 3%. Southbound Stock Connect ETFs moved in the same direction as the wider market, with biotech leading the gains and Hong Kong-Korea tech and iShares Core MSCI China Index ETF leading the declines.
Hong Kong recent listings showed divergent performance, with EXCELLAND ROBOTICS topping the list with a gain of 188.30% and TH MEDICAL-B ranking last with a decline of 50.42%. MEIG, ZHAOWEI and ESTUN saw their lock-up restrictions lifted, with weekly changes of 2.81%, -3.70% and -10.07%, respectively. CIG topped the list with average daily turnover of HK$2.095 billion. QIYUNSHAN FOOD led with a deviation of 968.75% from its issue price, while REFIRE fell the deepest below its issue price, at 94.30%. DELTON will see 20.6745 million shares released from lock-up next week, with the date after the reporting period.
